Revvity Raises 2026 Outlook As Adjusted Operating Margin Climbs To 28.7%
The lab-science company posted third-quarter revenue of $729 million and now sees full-year adjusted earnings of $5.40-$5.45 a share.
Revvity, which makes instruments, reagents, software and services for researchers and clinical labs, raised its full-year guidance after reporting third-quarter revenue of $729 million, up from $699 million a year earlier. CEO Prahlad Singh said "broad-based growth and strong execution drove results meaningfully ahead of our expectations."
Margins widen in both segments
Pro forma revenue, which strips out the Chinese immunodiagnostics business Revvity has agreed to sell, was $710 million, up 7% from $660 million. Pro forma organic growth was also 7%.
Adjusted operating margin reached 28.7%, from 26.1% a year ago. Adjusted earnings per share from continuing operations rose to $1.38 from $1.18, and earnings under standard accounting climbed to $0.56 from $0.41.
Life Sciences revenue was $380 million, against $343 million. Pro forma revenue there rose 11%, and organic revenue rose 9%. Its adjusted operating margin was 31.5%, from 29.5%.
Diagnostics revenue was $349 million, down from $356 million as reported. Pro forma revenue rose 4% and pro forma organic revenue rose 5%. Its adjusted margin jumped to 29.9% from 25.1%.
The new full-year guidance
For 2026, Revvity forecasts pro forma revenue of about $2.86 billion, pro forma organic growth of about 5% and pro forma adjusted earnings per share of $5.40-$5.45. Guidance excludes the China unit.
Revvity's business spans two segments. Life Sciences serves pharmaceutical, biotech and academic customers, and Diagnostics sells to hospitals and medical labs.
The China sale and a cleaner balance sheet
Revvity signed a definitive agreement on July 31 to sell its China immunodiagnostics business for up to $200 million, subject to adjustments and conditions. That unit made up about 6% of 2025 revenue. Management believes it is probable the deal closes by the end of 2027.
In the quarter, the company paid $571 million on its senior unsecured notes. Its balance sheet at quarter-end showed no current portion of long-term debt, against $589 million at the end of 2025.
Revvity holds its Investor Day on Friday, November 13, at 9:00 a.m. ET.
Management will lay out its business initiatives and financial outlook at the November 13 Investor Day.
Sources
- 8-K Filing — REVVITY, INC. (RVTY) — SEC EDGAR
- Exhibit q32026pressrelease.htm — REVVITY, INC. 8-K exhibit — SEC EDGAR
- Exhibit q32026proformafinancialsta.htm — REVVITY, INC. 8-K exhibit — SEC EDGAR
- Revvity: Q3 Earnings Snapshot — Associated Press
- Revvity (RVTY) Tops Q3 Earnings and Revenue Estimates — Yahoo Finance
- Revvity: Q3 Earnings Snapshot – WTOP News — wtop.com
- Revvity: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Revvity: Q3 Earnings Snapshot | 9news.com — Associated Press